11 completed, 4 recruiting, 4 unknown, 2 terminated. 23 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Completed 11, Recruiting 4, Unknown 4, Terminated 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 5 | Completed 2, Unknown 2, Recruiting 1 |
Follow IFL protocol: new trials by email Literature Review of IFL protocol trials Research Report on IFL protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) Petosemtamab, Cetuximab, FOLFIRI - Left-sided Colorectal Cancer | Phase 3 | Recruiting | Genmab | 960 | 2026-08-11 | 2026-10-06 |
| A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma ZG006, 5-fluorouracil, Calcium folinate and Irinotecan - Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 240 | 2026-07-01 | 2026-05-19 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer Pumitamig, FOLFOX, FOLFIRI - Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 990 | 2025-12-31 | 2026-10-23 |
| Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) mFOLFOX6, mFOLFOXIRI, FOLFIRI - Colorectal Cancer | Phase 3 | Recruiting | Dominik Paul Modest | 507 | 2021-12-06 | 2025-12-12 |
| Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC Cetuximab, mFOLFOX6, FOLFIRI - Colorectal Cancer | Phase 2 / Phase 3 | Unknown | Ruijin Hospital | 200 | 2021-11-01 | 2021-04-30 |
| A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma Surufatinib plus Toripalimab, 5-fluorouracil, Calcium folinate and Irinotecan - Advanced Neuroendocrine Carcinoma | Phase 3 | Unknown | Hutchison Medipharma Limited | 194 | 2021-09-18 | 2023-12-13 |
| Induction Chemotherapy for Locally Recurrent Rectal Cancer Combination drug, Chemoradiotherapy, Surgery locally recurrent rectal cancer - Recurrent Rectal Cancer | Phase 3 | Recruiting | Catharina Ziekenhuis Eindhoven | 364 | 2020-11-13 | 2022-09-06 |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol - Metastatic Colon Cancer, Stage III Colon Cancer | Phase 3 | Active not recruiting | Massachusetts General Hospital | 400 | 2020-04-16 | 2026-09-09 |
| mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy FOLFIRI - Metastatic Colorectal Cancer | Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 328 | 2020-01-01 | 2022-05-05 |
| Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy FOLFIRI, Ramucirumab, Paclitaxel - Advanced Gastric or EGJ Cancer | Phase 2 / Phase 3 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 429 | 2017-05-10 | 2026-07-02 |
| Cetuximab Monotherapy Maintenance Treatment in mCRC Cetuximab, mFOLFOX6, FOLFIRI - Colorectal Cancer | Phase 2 / Phase 3 | Unknown | Ruijin Hospital | 500 | 2016-11-01 | 2016-11-30 |
| Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) mFOLFOX6, FOLFIRI, Pembrolizumab - Colorectal Carcinoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 307 | 2015-11-30 | 2024-10-03 |
| Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis Raltitrexed-based chemotherapy, 5-fluorouracil-based chemotherapy - Colorectal Cancer, Liver Metastasis | Phase 3 | Terminated | Zhejiang University | 360 | 2015-10-11 | 2020-07-14 |
| Erbitux MEtastatic Colorectal Cancer Strategy Study Cetuximab, FOLFIRI - Antineoplastic Agents | Phase 3 | Completed | Armando Orlandi | 607 | 2015-02-01 | 2020-03-31 |
| Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer Masitinib (AB1010), FOLFIRI - Metastatic Colorectal Cancer | Phase 3 | Terminated | AB Science | 123 | 2014-01-01 | 2019-02-11 |
| Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen AFLIBERCEPT AVE0005, FOLFIRI - Colorectal Cancer Metastatic | Phase 3 | Completed | Sanofi | 781 | 2012-05-30 | 2018-04-17 |
| Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone Panitumumab, FOLFIRI - Metastatic Colorectal Cancer | Phase 3 | Completed | Amgen | 1186 | 2006-06-30 | 2022-09-23 |
| Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer bevacizumab, cetuximab, FOLFOX or - Colorectal Cancer | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 2334 | 2005-11-01 | 2026-08-07 |
| Metastatic Gastric Cancer FFCD 03-07 ECC, FOLFIRI - Stomach Cancer, Neoplasm Metastasis | Phase 3 | Completed | University Hospital, Toulouse | 416 | 2005-06-01 | 2011-10-12 |
| PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study Oxaliplatin Based Chemotherapy, Panitumumab, Irinotecan Based Chemotherapy - Colorectal Cancer | Phase 3 | Completed | Amgen | 1053 | 2005-06-01 | 2018-10-17 |
Showing 20 of 23. Sign in to see all of them.
Colorectal Neoplasms (14) · Rectal Neoplasms (3) · Colonic Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Stomach Neoplasms (2) · Carcinoma, Neuroendocrine (1) · Margins of Excision (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Amgen (2) · Ruijin Hospital (2) · AB Science (1) · Alliance for Clinical Trials in Oncology (1) · Armando Orlandi (1) · Bristol-Myers Squibb (1) · Catharina Ziekenhuis Eindhoven (1) · Dominik Paul Modest (1) · Genmab (1) · Gruppo Oncologico del Nord-Ovest (1) · Hutchison Medipharma Limited (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Massachusetts General Hospital (1) · Merck Sharp & Dohme LLC (1)
China (5) · Italy (5) · United States (5) · France (4) · Germany (4) · Belgium (3) · Canada (3) · Netherlands (3) · United Kingdom (3) · Austria (2) · Brazil (2) · Chile (2) · Czechia (2) · Mexico (2) · Norway (2)
Alan Venook, MD (1) · Alfredo Falcone, MD (1) · Aparna Parikh, MD (1) · Ding Ke-Feng, PHD/MD (1) · Dominik Modest, Prof. Dr. (1) · Jason Wu (1) · Julien Taieb, PhD, MD (1) · Jun Zhang, MD & Ph.D (1) · Lin Shen, Prof. (1)
PMID 16356309, PMID 17553204, PMID 22070868, PMID 23955585, PMID 25287828, PMID 26049686, PMID 26341920, PMID 26861604, PMID 28632865, PMID 29627309, PMID 30679026, PMID 31042420, PMID 31221542, PMID 31378656, PMID 31408415, PMID 31548349, PMID 31902066, PMID 33264544, PMID 33812497, PMID 35202974, PMID 35366831, PMID 35427471, PMID 36067452, PMID 36369901, PMID 37337155, PMID 38181312, PMID 38457761
2014 (1), 2015 (1), 2025 (1), U10CA037447 (1)